Shah Capital Ends Proxy Fight at Novavax After Sanofi Deal Boost
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with Sanofi (NASDAQ:SNY), Shah Capital has withdrawn its proxy campaign against the re-election of the company’s directors at its annual meeting.